A pharmaceutical composition comprising a therapeutically effective and non-severe-symptomatic-hypercalcemia-inducing amount of a first compound and a second compound; wherein the first compound is a vitamin D prodrug comprising a vitamin D-drug moiety and a pro moiety, wherein the pro moiety is selected from the group consisting of a glycone moiety and a sulfate moiety, wherein the vitamin D prodrug has the structure of Formula: wherein T is hydrogen or a =CH 2 group; X 1 is selected from the group consisting of -OH and -OR 1; U is hydrogen, C 1 -C 6 alkenyl, C 1 -C 6 alkyl, -OH, or -O-(C 2 -C 4 alkyl)-OH; R is a double bond or an epoxy group; R 1 is hydrogen, -SO 3, or a straight- or branched-chain glycone moiety comprising 1-20 glycone units, or R 1 is an orthoester glycoside moiety of Formula: wherein A represents a glycofuranosyl or glycopyranosyl ring; R 2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C 1 -C 4 alkyl, C 1 -C 4 alkoxy; or naphthyl; and R 3 is hydrogen, -SO 3, or a straight- or branched-chain glycone moiety comprising 1-20 glycone units; and Z is a hydrogen or a saturated or unsaturated, substituted or unsubstituted, straight-chain or branched C 1 -C 18 hydrocarbon group having a formula as represented by Formula: wherein the bond between C-22 and C-23 is a single or double bond; Y 2 is hydrogen, fluorine, C 1 -C 6 alkyl, -OH, or -OR 1; Z 2 is hydrogen, fluorine, C 1 -C 6 alkyl, -OH, or -OR 1; Q a is -CF 3 or -CH 2 X 2; Q b is -CF 3 or -CH 3; X 2 is hydrogen, -OH, or -OR 1; W is -CH-CH 3 or -O-; V is CH 2, CH, or -O-, wherein W and V are not both -O-; and "= = =" is either a single bond between Q a and Q b or a hydrogen atom on both Q a and Q b, wherein when "= = =" is a single bond, X 2 is H; wherein at least one of the R 1 comprises at least one glycone moiety or at least one -SO 3 moiety; wherein the second compound comprises a first moiety and a second moiety, wherein the first moiety is selected from the group consisting of a glycone moiety and a sulfate moiety, and wherein the second moiety is a 24-hydroxylase inhibitor selected from the group consisting of 25-hydroxyvitamin D 2, 24,25-dihydroxyvitamin D 2, 25-hydroxyvitamin D 3, 24,25-dihydroxyvitamin D 3, 25-hydroxyvitamin D 4, 24,25-dihydroxyvitamin D 4, 25-hydroxyvitamin D 5, and 24,25-dihydroxyvitamin D 5, for use in selectively treating a vitamin D-sensitive disease in the intestine. wherein T is hydrogen or a =CH 2 group; X 1 is selected from the group consisting of -OH and -OR 1; U is hydrogen, C 1 -C 6 alkenyl, C 1 -C 6 alkyl, -OH, or -O-(C 2 -C 4 alkyl)-OH; R is a double bond or an epoxy group; R 1 is hydrogen, -SO 3, or a straight- or branched-chain glycone moiety comprising 1-20 glycone units, or R 1 is an orthoester glycoside moiety of Formula: wherein A represents a glycofuranosyl or glycopyranosyl ring; R 2 is hydrogen, lower alkyl, aralkyl, or aryl, with the proviso that aryl is phenyl or phenyl substituted by chloro, fluoro, bromo, iodo, lower C 1 -C 4 alkyl, C 1 -C 4 alkoxy; or naphthyl; and R 3 is hydrogen, -SO 3, or a straight- or branched-chain glycone moiety comprising 1-20 glycone units; and Z is a hydrogen or a saturated or unsaturated, substituted or unsubstituted, straight-chain or branched C 1 -C 18 hydrocarbon group having a formula as represented by Formula: wherein the bond between C-22 and C-23 is a single or double bond; Y 2 is hydrogen, fluorine, C 1 -C 6 alkyl, -OH, or -OR 1; Z 2 is hydrogen, fluorine, C 1 -C 6 alkyl, -OH, or -OR 1; Q a is -CF 3 or -CH 2 X 2; Q b is -CF 3 or -CH 3; X 2 is hydrogen, -OH, or -OR 1; W is -CH-CH 3 or -O-; V is CH 2, CH, or -O-, wherein W and V are not both -O-; and "= = =" is either a single bond between Q a and Q b or a hydrogen atom on both Q a and Q b, wherein when "= = =" is a single bond, X 2 is H; wherein at least one of the R 1 comprises at least one glycone moiety or at least one -SO 3 moiety; wherein the second compound comprises a first moiety and a second moiety, wherein the first moiety is selected from the group consisting of a glycone moiety and a sulfate moiety, and wherein the second moiety is a 24-hydroxylase inhibitor selected from the group consisting of 25-hydroxyvitamin D 2, 24,25-dihydroxyvitamin D 2, 25-hydroxyvitamin D 3, 24,25-dihydroxyvitamin D 3, 25-hydroxyvitamin D 4, 24,25-dihydroxyvitamin D 4, 25-hydroxyvitamin D 5, and 24,25-dihydroxyvitamin D 5, for use in selectively treating a vitamin D-sensitive disease in the intestine.